Eiger BioPharmaceuticals Inc

+0.03 (+0.69%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)193.93M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$5.07 Million
Adjusted EPS-$0.53
See more estimates
10-Day MA$4.26
50-Day MA$5.52
200-Day MA$6.73
See more pivots

Eiger BioPharmaceuticals Inc Stock, NASDAQ:EIGR

2155 Park Boulevard, 2155 Park Boulevard, Palo Alto, California 94306-1543
United States of America
Phone: +1.650.272.6138
Number of Employees: 43


Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.